SC1-BHC-09-2018
SC1-BHC-09-2018
6 projects · €79,714,762 total EU contribution (project-level) · 78 participating organizations · 17 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€79,714,762
Countries active
Participant organizations by country (headquarters in CORDIS).
- Germany (17)
- Netherlands (11)
- France (9)
- Italy (9)
- UK (7)
- Spain (4)
- BE (3)
- CH (3)
- FI (3)
- HU (2)
- IE (2)
- SE (2)
- US (2)
- CA (1)
- HK (1)
- IL (1)
- NO (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- NANTES UNIVERSITE3 projects · FR
- CHARITE - UNIVERSITAETSMEDIZIN BERLIN2 projects · DE
- MHH2 projects · DE
- NMI2 projects · DE
- UMC UTRECHT2 projects · NL
- VUB2 projects · BE
- A2F ASSOCIATES1 projects · UK
- Leiden University Medical Center1 projects · NL
- AO-FORSCHUNGSINSTITUT DAVOS1 projects · CH
- ASPHALION1 projects · ES
- ASTRAZENECA AB1 projects · SE
- BBS1 projects · NL
Projects
Page 1 of 1
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
Unlocking Precision Gene Therapy UPGRADE · 825825 | H2020 | €14,995,830 | €1,107,000 | Details |
ENDOSCAPE, a clinically applicable non-viral gene delivery technology ENDOSCAPE · 825730 | H2020 | €6,850,644 | €488,750 | Details |
Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials RESHAPE · 825392 | H2020 | €13,137,396 | €0 | Details |
CardioReGenix: Development of Next-Generation Gene Therapies for Cardiovascular Disease CardioReGenix · 825670 | H2020 | €14,839,774 | €1,013,675 | Details |
EXpanding Platforms for Efficacious mRNA Therapeutics EXPERT · 825828 | H2020 | €14,931,338 | €815,250 | Details |
Induced pluripotent stem cell-based therapy for spinal regeneration iPSpine · 825925 | H2020 | €14,959,781 | €321,250 | Details |